Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways

Abstract

Prostate cancer (PC) is the most common malignancy in males. Despite high response rates and clinical benefits, androgen-ablation therapy is ineffective for advanced or relapsed PC because of the emergence of aggressive castration-resistant prostate cancer (CRPC). Through our genome-wide gene expression analysis of PC cells purified from clinical CRPC tissues, we here identified a novel molecular target, PKIB (cAMP-dependent protein kinase inhibitor-β), which was overexpressed specifically in CRPCs and aggressive PCs. Immunohistochemical analysis confirmed its overexpression in CRPCs and its strong correlation with high Gleason scores of PCs. Knockdown of PKIB by siRNA resulted in drastic growth suppression of PC cells, and, concordantly, exogenous introduction of PKIB into PC cells enhanced their growth and mobility. We found the direct interaction between PKIB and cAMP-dependent protein kinase A catalytic subunit (PKA-C), and showed that knockdown of PKIB in PC cells diminished the nuclear translocation of PKA-C. Knockdown of PKIB also decreased the phosphorylation level of Akt at Ser473 in PC cells, and exogenous PKIB introduction enhanced Akt phosphorylation in PC cells by incorporating with endogenous PKA-C kinase. In vitro kinase assay validated the recombinant PKIB enhanced phosphorylation of Akt at Ser473 by PKA-C kinase. These findings show that PKIB and PKA-C kinase can have critical functions of aggressive phenotype of PCs through Akt phosphorylation and that they should be a promising molecular target for PC treatment.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Burgering BM, Kops GJ . (2002). Cell cycle and death control: long live Forkheads. Trends Biochem Sci 27: 352–360.

    Article  CAS  Google Scholar 

  • Chio CC, Chang YH, Hsu YW, Chi KH, Lin WW . (2004). PKA-dependent activation of PKC, p38 MAPK and IKK in macrophage: implication in the induction of inducible nitric oxide synthase and interleukin-6 by dibutyryl cAMP. Cell Signal 16: 565–575.

    Article  CAS  Google Scholar 

  • Cox ME, Deeble PD, Bissonette EA, Parsons SJ . (2000). Activated 3′,5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendcrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 275: 13812–13818.

    Article  CAS  Google Scholar 

  • Dalton GD, Dewey WL . (2006). Protein kinase inhibitor peptide (PKI): a family of endogenous neuropeptides that modulate neuronal cAMP-dependent protein kinase function. Neuropeptides 40: 23–34.

    Article  CAS  Google Scholar 

  • Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231–241.

    Article  CAS  Google Scholar 

  • Deeble PD, Cox ME, Frieson Jr HF, Sikes RA, Palmer JB, Davidson RJ et al. (2007). Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 67: 3663–3672.

    Article  CAS  Google Scholar 

  • Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM . (1998). Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16: 1743–1748.

    Article  CAS  Google Scholar 

  • Feldman BJ, Feldman D . (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34–45.

    Article  CAS  Google Scholar 

  • Filippa N, Sable C, Filloux C, Hemmings B, Van Obberghen E . (1999). Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase. Mol Cell Biol 19: 4989–5000.

    Article  CAS  Google Scholar 

  • Gamm DM, Uhler MD . (1995). Isoform–specific differences in the potencies of murine protein kinase inhibitors are due to unconserved amino-terminal residues. J Biol Chem 270: 7227–7232.

    Article  CAS  Google Scholar 

  • Gronberg H . (2003). Prostate cancer epidemiology. Lancet 361: 859–864.

    Article  Google Scholar 

  • Grossmann ME, Huang H, Tindall DJ . (2001). Androgen receptor signaling in androgen refractory prostate cancer. J Natl Cancer Inst 93: 1687–1697.

    Article  CAS  Google Scholar 

  • Hay N . (2005). The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179–183.

    Article  CAS  Google Scholar 

  • Hsing AW, Devesa SS . (2001). Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23: 3–13.

    Article  CAS  Google Scholar 

  • Knighton DR, Zheng JH, Teneyck LF, Xuong NH, Taylor SS, Sowadski JM . (1991). Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253: 414–420.

    Article  CAS  Google Scholar 

  • Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S et al. (2004). Phosphorylation of Akt(Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232–5236.

    Article  CAS  Google Scholar 

  • Lalli E, Sassone-Corsi P . (1994). Signal transduction and gene regulation: the nuclear response to cAMP. J Biol Chem 269: 17359–17362.

    CAS  PubMed  Google Scholar 

  • Majumder PK, Sellers WR . (2005). Akt-regulated pathways in prostate cancer. Oncogene 24: 7465–7474.

    Article  CAS  Google Scholar 

  • Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R et al. (2002). Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8: 1168–1171.

    PubMed  Google Scholar 

  • McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V et al. (2008). Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68: 1618–1624.

    Article  CAS  Google Scholar 

  • Miller WR . (2002). Regulatory subunits of PKA and breast cancer. Ann NY Acad Sci 968: 37–48.

    Article  CAS  Google Scholar 

  • Mitsiades CS, Mitsiades N, Koutsilieris M . (2004). The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 4: 235–256.

    Article  CAS  Google Scholar 

  • Orloff MS, Eng C . (2008). Genetic and phenotypic heterogeneity in the PTEN hamartoma tumor syndrome. Oncogene 27: 5387–5397.

    Article  CAS  Google Scholar 

  • Pap M, Cooper GM . (1998). Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 273: 19929–19932.

    Article  CAS  Google Scholar 

  • Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. (2004). Docetaxel and estramustine compared with mitoxantrone and predonisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520.

    Article  CAS  Google Scholar 

  • Sadar MD . (1999). Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 274: 7777–7783.

    Article  CAS  Google Scholar 

  • Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . (2005). Phosphorylation and regulation of Akt/PKB by Rictor-mTOR complex. Science 307: 1098–1101.

    Article  CAS  Google Scholar 

  • Scheid MP, Woodgett JR . (2001). PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2: 760–768.

    Article  CAS  Google Scholar 

  • Scher HI, Sawyers CL . (2006). Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253–8261.

    Article  Google Scholar 

  • Shaywitz AJ, Greenberg ME . (1999). CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68: 821–861.

    Article  CAS  Google Scholar 

  • Stork PJ, Schmitt JM . (2002). Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12: 258–266.

    Article  CAS  Google Scholar 

  • Tamura K, Furihata M, Tsunoda T, Ashida A, Takata R, Obara W et al. (2007). Molecular features of hormone-refractory prostate cancer cells by genome-wide gene-expression profiles. Cancer Res 67: 5117–5125.

    Article  CAS  Google Scholar 

  • Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. (2004). Docetaxel plus predonisone or mitoxantrone plus predonisone for advanced prostate cancer. N Engl J Med 351: 1502–1512.

    Article  CAS  Google Scholar 

  • Tasken K, Aandahl EM . (2004). Localized effects of cAMP mediated by distinct routes of protein kinase A. Physol Rev 84: 137–167.

    CAS  Google Scholar 

  • Taylor SS, Kim C, Vigil D, Haste NM, Yang J, Wu J et al. (2005). Dynamics of signaling by PKA. Biochim Biophys Acta 1754: 25–37.

    Article  CAS  Google Scholar 

  • Vivanco I, Sawyers CL . (2002). The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2: 289–301.

    Article  Google Scholar 

  • Wen W, Harootunian AT, Admas SR, Feramisco J, Tsien RY, Meinkoth JL et al. (1994). Heat-stable inhibitors of cAMP-dependent protein kinase carry a nuclear export signal. J Biol Chem 269: 32214–32220.

    CAS  PubMed  Google Scholar 

  • Wiley JC, Wailes LA, Idzerda RL, McKnight GS . (1999). Role of regulatory subunits and protein kinase inhibitor (PKI) in determining nuclear localization and activity of the catalytic subunit of protein kinase A. J Biol Chem 274: 6381–6387.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Ms Mami U and Ms Hitomi Uchida for their technical assistance, and Dr Ryo Takada at Iwate Medical University for his preparation of prostate cancer tissues. This work was supported by Grant-in-Aid for Scientific Research #18590323 (H Nakagawa) and Research for the Future Program Grants #00L01402 (Y Nakamura) from the Japan Society for the Promotion of Science.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H Nakagawa.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chung, S., Furihata, M., Tamura, K. et al. Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. Oncogene 28, 2849–2859 (2009). https://doi.org/10.1038/onc.2009.144

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2009.144

Keywords

This article is cited by

Search

Quick links